appears to be associated with relative long-term survival in select cases. [19] [20] [21] [22] [23] Overall, RT has a poor prognosis, with a median survival of only 1-2 years. 3, 5 The landscape of CLL management has changed dramatically with the emergence of several novel targeted agents, such as Bruton's tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib, phosphoinositide 3-kinase δ (PI3Kδ ) inhibitors idelalisib and duvelisib, and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. It is unclear whether these novel agents affect the risk, prognosis and management of RT. In de novo DLBCL, the prognostic roles of cell of origin (COO), Myc and Bcl-2 double expression, and MYC, BCL2 and/or BCL6 gene rearrangements have been well recognized. [24] [25] [26] [27] [28] [29] However, the potential impact of these molecular markers on the outcome of DLBCL-type RT has not been well studied.
In this study, we report the clinical characteristics, treatment pattern, and outcomes of a large series of RT patients (n=204) from a single center over more than two decades including the era of novel agents (from 2012 to the present). The potential prognostic impact of prior CLL treatment as well as CLL-and RT-related molecular markers were also explored.
Methods

Patients
This study was approved by the Mayo Clinic Institutional Review Board. All patients were identified from the Mayo Clinic CLL database which includes consecutive CLL patients evaluated in the Division of Hematology at Mayo Clinic, Rochester, MN, USA. 2, 30, 31 CLL patients who developed biopsy-proven RT between April 1993 and April 2018 were identified from the database. For this study, the focus was RT to DLBCL (including high grade B-cell lymphoma, such as double-/triple-hit lymphoma which is now known as high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements); transformations to Hodgkin lymphoma or other histology were excluded. Clinical, pathological, and molecular characteristics [IGHV mutation, CLL fluorescence in situ hybridization (FISH)] and all treatment information during the CLL phase were abstracted from the database. Clinical, pathological and molecular characteristics [CLL FISH, TP53 somatic mutation, COO by Hans algorithm, Myc/Bcl-2 expression by immunohistochemistry (IHC), MYC/BCL2/BCL6 rearrangement by FISH, CLL and RT clonal relationship by immunoglobulin gene rearrangement], treatment course, clinical response to treatment as determined by treating physician, and survival information after RT was abstracted by chart review. On IHC, the cut-off value for positivity was 40% for Myc, and 50% for Bcl-2. Our institution started to routinely test for Myc expression by IHC and MYC rearrangement by FISH in all DLBCL cases in 2012; therefore, we have missing information on IHC as well as FISH results in patients diagnosed with RT prior to this.
Statistical analysis
The date of RT diagnosis was defined as the date of the biopsy which led to the pathological diagnosis of RT. The time to transformation was defined as the time from CLL diagnosis to RT diagnosis. Overall survival (OS) was defined as the time from RT diagnosis to death from any cause. Time-to-event data were analyzed using the Kaplan-Meier method. Cox proportional hazards models were used to analyze associations between OS and various factors. P<0.05 was considered statistically signifi- 
Results
Clinical characteristics in the chronic lymphocytic leukemia phase
A total of 204 patients with CLL who developed RT were identified. Baseline characteristics at CLL diagnosis are shown in Online Supplementary Table S1 . The median age at CLL diagnosis was 62 years (range 22-85), and 148 (72.5%) were male. Seventy-one (71.0%) of 100 patients tested had unmutated IGHV. CLL FISH detected del(17p) in 33 (25.4%), del(11q) in 18 (13.8%), and trisomy 12 in 19 (14.6%) of 130 patients. Forty-seven (66.2%) of 71 patients were high or very high risk by CLL-IPI score (≥4).
Clinical characteristics at Richter transofrmation diagnosis
Median time to transformation was 4.7 years (range 0-34.5) ( Table 1 ). Prior to RT, 69 (33.8%) patients received no treatment for CLL, 108 (52.9%) received chemoimmunotherapy (CIT) only, and 27 (13.2%) received at least one novel agent (idelalisib, ibrutinib, or venetoclax) for CLL; 19 patients received CIT previously and developed RT on novel agents (17 ibrutinib, 1 idelalisib, 1 venetoclax), 6 patients received novel agents previously and developed RT on subsequent treatment (1 rituximab-bendamustine, 3 rituximab-corticosteroid, and 2 rituximab alone), and 2 other patients developed RT on frontline ibrutinib. Median lines of CLL therapy prior to RT was 2 (range 0-13).
Thirty-three patients were diagnosed with RT prior to 2002 (when rituximab was not routinely available), 70 patients were diagnosed between 2002 and 2011, and 101 patients were diagnosed in 2012 or later (when ibrutinib had become available). The median age at RT diagnosis was 69 years (range 
Richter transformation treatment and outcome
Pattern of first-line treatment for RT is shown in Table  2 . The most commonly used first-line treatment was an R-CHOP-like regimen (n=114, 65.5%). Twelve (6.9%) patients received platinum or high-dose cytarabine containing chemotherapy; 21 (12.1%) patients received other chemotherapy (6 with DA-EPOCH-R-like regimen, 15 with others including ProMACE-CytaBOM, R-CEPP, infusional CDE, R-CVP, R-bendamustine, R-gemcitabine/prednisone, high dose methotrexate-based regimen). Nineteen (10.9%) patients received novel agents: ibrutinib (n=4), venetoclax (n=1), ibrutinib plus venetoclax (n=3), pembrolizumab (n=7), pembrolizumab plus ibrutinib (n=1), CD19 monoclonal antibody (n=1), everolimus (n=1), everolimus plus panobinostat (n=1). Eight (4.6%) patients received palliative therapy defined as rituximab, corticosteroids, radiation therapy, alone or in combination.
Clinical response (assessed by treating physician) to first-line treatment was complete response (CR) in 54 (36.0%), partial response (PR) in 37 (24.0%), stable disease (SD) in 18 (12.0%), and progressive disease (PD) in 42 (28.0%) of 150 patients. The median follow up after RT was 67.0 months, and there were a total of 150 deaths. The median OS after RT diagnosis was 12.0 months ( Figure 1A) .
Survival by clinical and molecular factors and treatment is summarized in Table 3 . The median OS was significantly better in patients who received no CLL treatment than those who received any CLL treatment, with a median OS of 46.3 versus 7.8 months (P<0.001) ( Figure 1B ). Among the 69 patients who received no CLL treatment, 31 had concurrent CLL and RT (i.e. RT diagnosis within 3 months of CLL diagnosis), with a median OS of 66.9 months; in the other 38 patients with sequential CLL and RT (median time to transformation 55.5 months), the median OS was 29.4 months (P=0.25) ( Figure 1C ). Among the 135 patients who had received treatment for CLL, patients with only one line of CLL treatment (n=31) had a trend of better OS compared to those with two or more lines of CLL treatment (n=104), with a median OS of 15.3 versus 5.8 months (P=0.09) ( Figure 1D ). Patients who received CIT only and those who received at least one novel agent for CLL had a continued from the previous page median OS of 7.1 and 12.0 months, respectively (P=0.28) ( Figure 1E ). There was no significant difference in median OS between younger (age≤65) and older (age>65) RT patients, with a median OS of 13.3 versus 11.3 months (P=0.07) ( Figure 2A ). Patients with elevated LDH had worse OS compared to those with normal LDH, with a median OS of 6.2 versus 39.9 months (P<0.0001) ( Figure 2B ). Bulky disease (nodal size ≥5 cm) was not associated with a worse OS (median OS of 8.0 vs. 14.6 months; P=0.13) (Online Supplementary Figure S1 ). Patients with TP53 disruption had a worse OS than those without (median OS 8.3 vs. 12.8 months; P=0.046) ( Figure 2C ). Other molecular characteristics, including IGHV mutation (Online Supplementary Figure S2 ), DLBCL COO (Online Supplementary Figure S3 ), Myc/Bcl-2 double expression ( Figure 2D ), MYC/BCL2/BCL6 double-/triple-hit status (Online Supplementary Figure S4) , and CLL and RT clonal relationship (Online Supplementary Figure S5) Figure S6 ). Patients treated with platinum or high-dose haematologica | 2020; 105(3) Supplementary Table S2 . The median age at RT diagnosis was 62 years (range 41-73). Ten patients did not receive any prior CLL treatment. Nineteen patients achieved a PR or better with 1-2 lines of treatment before proceeding to SCT. The median time from RT diagnosis to SCT was 6.8 months (range 3.3-42.3). None of the four allogeneic SCT patients died although the post-SCT follow up was still relatively short for three of them ( Figure 3A) . Thirteen of the 20 autologous SCT patients had a post-SCT survival greater than two years ( Figure 3A) . Overall, the 24 SCT patients had a median post-SCT survival of 55.4 months ( Figure 3B ).
Discussion
To the best of our knowledge, this is the largest series of CLL patients with biopsy-proven DLBCL-type RT with a long follow up. Our results showed that patients with 
Prior CLL treatment All patients (%) None (%) Chemoimmunotherapy At least one only (%) novel agent (%)
R-CHOP-like regimen 1 114 (65.5%) 49 (81.7%) 60 (66.7%) 5 (20.8%) Platinum or high dose cytarabine containing chemotherapy 2 12 (6.9%) 1 (1.7%) 10 (11.1%) 1 (4.2%) Other chemotherapy 3 21 (12.1%) 9 (15.0%) 10 (11.1%) 2 (8.3%) Novel agents 4 19 (10.9%) 0 (0.0%) 4 (4.4%) 15 (62.5%) Palliative therapy 5 8 (4.6%) 1 (1.7%) 6 (6.7%) 1 (4.2%) Missing 
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DLBCL-type RT overall had a poor prognosis with a median OS of only 12 months. Patients with RT who received no prior CLL treatment had a significantly better OS, with a median OS of approximately four years. Our singular finding is that patients who received no prior CLL therapy had a favorable outcome. Further proof of this finding was provided in a prior phase II trial of ofatumumab in combination with CHOP for newly diagnosed RT, where patients who received no prior CLL treatment had significantly better OS (median unreached at 24 months vs. approx. 6 months). 32 A recent Danish National CLL Registry study of RT (over 8 years with multiple histologies) also showed similar results, with a median OS of 6.16 year in patients with untreated CLL versus 1.49 years in patients with treated CLL. 11 The observed OS differences in these studies may be due to different biology in untreated patients. Further to this finding, RT patients who received only one line of CLL therapy had a trend of better OS compared to those who received two or more lines of prior CLL therapies in our study, and two other studies also demonstrated that fewer lines of prior CLL therapy was associated with better RT survival, 18, 19 supporting the hypothesis that less therapy of CLL may be associated with less chemoresistance of RT. Of note, patients who were diagnosed with CLL and RT within three months (defined as concurrent RT) had a particularly favorable outcome, with a median OS of approximately six years. We suspect that the concurrent RT cases were more likely clonally unrelated (to the CLL) and resemble de novo DLBCL. This aspect warrants future studies. Based on our data, patients with concurrent RT may benefit from the typical therapy for de novo DLBCL.
TP53 disruption (i.e. del(17p) and/or TP53 mutation) was associated with a worse prognosis of RT in the univariate analysis, consistent with a number of prior studies. 8, 12, 18, [32] [33] [34] Of note, TP53 disruption was not an independent prognostic factor of OS in the multivariable analysis in our study. Rossi et al. showed that TP53 disrup- 
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tion was an independent prognostic factor of RT survival. 8 Four other studies did not test for TP53 somatic mutation and reported inconsistent results regarding the independent prognostic role of del(17p). 8, 12, 33, 34 Given only 27 (13%) of our patients underwent the TP53 somatic mutation test, we likely underestimated the proportion of RT patients who had TP53 disruption, and thus might have underestimated the negative impact of this molecular abnormality on RT outcomes in our cohort.
The prognostic roles of COO, double expressor and double-hit status in de novo DLBCL have been well established. [24] [25] [26] [27] [28] [29] In this study, we found that these molecular markers were not prognostic for RT survival. Indeed, Eyre et al. showed that COO and Myc expression status did not influence RT survival in the O-CHOP trial, 32 and Fidai et al. showed that MYC and/or BCL2 genetic alterations did not impact RT outcome in a retrospective study. 33 RT and de novo DLBCL are likely different diseases given the known distinct genomic abnormalities, 5, 35 and the impacts of COO and double expressor/double-hit status may therefore be different. We should note that molecular characterizations of COO and double expressor/double-hit status were incomplete in our dataset, and interpretation of these results should be made with caution.
In terms of other relevant prognostic factors, older age and elevated LDH were associated with worse OS in RT, consistent with the MD Anderson data. 19 Clonal relationship between CLL and RT was reported to be a critical prognostic factor, with a much better outcome in clonally unrelated RT. 8, 36 Due to the difficulty of obtaining paired CLL and RT samples (at RT diagnosis) and a lack of universal assessment in our routine clinical practice, we only have a limited number of cases (<5%) in which the CLL and RT clonal relationship was reported. This difficulty is consistent with clinical experiences shared among several different academic centers. While we did not see a statistically significant association of clonal relationship with RT survival, this should not be taken as evidence that goes against prior studies. CLL IGHV mutation status was not associated with RT survival in our study. Prior studies were inconsistent regarding the prognostic role of CLL IGHV mutation in RT survival, with positive association reported in two studies (one in univariate analysis only, the other with only 16 RT patients) 11, 34 but not others. 8, 18 It remains unclear whether CLL IGHV mutation status is associated with RT outcome.
In our cohort, RT patients who were exposed to at least one novel agent (predominantly ibrutinib) for CLL treatment had a median OS of 10.9 months, similar to those whose CLL were treated with CIT only, and compares favorably to prior data. [37] [38] [39] A number of studies have shown that RT that developed on novel agents had poor outcome, with a median OS of approximately 2-3.5 months if developed on ibrutinib [37] [38] [39] and approximately 12 months if developed on venetoclax. 40 In these studies, RT was primarily treated with R-CHOP-or R-EPOCH-like regimens. For our RT patients previously exposed to novel agents for CLL, approximately two-thirds were treated with novel agents (e.g. pembrolizumab, ibrutinib and venetoclax, etc.) and only one-third were treated with R-CHOP-like or other chemotherapy at first line. The efficacy of novel agents in treating RT has been reported by a number of studies. [41] [42] [43] [44] [45] [46] For example, pembrolizumab demonstrated encouraging efficacy in patients with RT, particularly those with prior exposure of ibrutinib. 43 Nivolumab in combination with ibrutinib and pembrolizumab in combination with umbralisib and ublituximab also demonstrated encouraging activity in treating RT. [45] [46] [47] In addition to the above studies, BTK inhibitors (NCT03899337), PI3K inhibitors (NCT03884998) and/or venetoclax (NCT03054896) based combination regimens (with or without chemotherapy) and other agents such as immunomodulatory drug lenalidomide (NCT03113695, NCT02005289), engineered anti-CD19 monoclonal antibody MOR208 (NCT02005289), and CD3/CD19 bispecific antibody blinatumumab (NCT03121534, NCT03931642) are actively being tested in clinical trials for RT. Chimeric antigen receptor (CAR) T cells are also showing promise in improving the outcome of RT 48 and are further tested in clinical trials (NCT03484702). Taken together, novel agents (e.g. pembrolizumab/nivolumab, ibrutinib and venetoclax) would seem to be very reasonable choices in patients who develop RT while receiving one of the targeted agents (e.g. ibrutinib, venetoclax, idelalisib) for CLL. However, it is important to note that despite promising results from multiple studies, [41] [42] [43] [44] [45] [46] [47] [48] further improvements to increase the efficacy and select optimal patients for different novel agents are clearly needed.
Patients who underwent SCT (n=24, 11.8%) in our cohort overall had a favorable outcome, with a median post-SCT survival of 55.4 months. The role of SCT in RT management has been explored previously. [19] [20] [21] [22] In the MD Anderson cohort, 20 (13.5%) of 148 RT patients were able to proceed to SCT (3 autologous, 17 allogeneic), and seven patients who underwent allogeneic SCT for consolidation had a favorable outcome with a 3-year OS of 75%. 19 A retrospective study by the European Group for Blood and Marrow Transplantation (EBMT) showed that post-remission SCT may benefit a subset of RT patients, with a 3-year OS of 59% for autologous SCT and 36% for allogeneic SCT. 20 Two recent single institution studies also reported somewhat favorable outcome of allogenic SCT in RT patients, with a 2-year OS of 44% in one study and a 4-year OS of 50% in the other. 21, 22 Collectively, these data suggest that select RT patients can benefit from SCT. One should be aware of the potential selection bias when interpreting the data, e.g. patients need to be relatively young and in good condition to proceed to SCT. For example, 10 of the 24 patients in our SCT cohort received no prior CLL treatment; patients were relatively younger, and most patients achieved a favorable response with 1-2 lines of RT therapy and then went on to SCT. We used substantially more autologous (n=20) than allogeneic (n=4) SCT. While allogeneic SCT target both the CLL and RT clones, an autologous SCT primarily eradicates the RT clone and spares the undesired high non-relapse mortality associated with allogeneic SCT.
Our study shows that RT has poor clinical outcomes in general. However, as a heterogeneous disease, its outcome is influenced significantly by prior CLL therapy status. One reason for the poor survival observed in RT after prior CLL therapy may be the known potential of CLL clones to undergo clonal evolution under the pressure of therapy. 49, 50 We propose a newer approach to manage RT based on their prior CLL therapy status. In treatmentnaïve patients and patients with clonally unrelated DLBCL, immunochemotherapy, in particular R-CHOPlike regimens, is the preferred approach in treating these RT. In patients exposed to targeted CLL therapies (including kinase inhibitors and BCL-2 inhibitor) or prior chemoimmunotherapies, the management of RT would likely need to incorporate novel agents, immunotherapy, and/or cellular therapy in clinical trials. SCT consolidation should still be considered in RT patients who achieve a good response to therapy. We fully expect that RT biology will continue to evolve with the changing landscape of CLL as management with novel agents are robustly moving to the front line. In support of this, recent data indicated that 70-80% of RT that developed on novel agents had TP53 disruption and/or complex karyotypes, both of which were prognostic of poor outcomes in RT. 39 It is hoped that our study can provide more valuable information on current management of RT and also point to areas of interest for future clinical trials and biological studies. 
